Evidence map›Paper›PMID 25401301›Full record

ArticleNature genetics2015

Spectrum of diverse genomic alterations define non-clear cell renal carcinoma subtypes.

Steffen Durinck, Eric W Stawiski, Andrea Pavía-Jiménez, Zora Modrusan, Payal Kapur, Bijay S Jaiswal, Na Zhang, Vanina Toffessi-Tcheuyap, Thong T Nguyen, Kanika Bajaj Pahuja and 31 more

Abstract readComparative Study
PubMed Full text at PMC Publisher
In one paragraph

Article in Nature genetics, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 191 papers, 4 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
191citing papers in PubMed, 4 pooled it
14.8field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

191 citing papers in PubMed, 4 syntheses or guidelines pooled it, 354 citations in OpenAlex.

  1. New developments in existing WHO entities and evolving molecular concepts: The Genitourinary Pathology Society (GUPS) update on renal neoplasia.Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc · 2021
    Guideline
  2. Guideline
  3. Pooled it
  4. Pooled it
  5. Trial
  6. Article
  7. [Molecular characteristics for poor prognosis related renal cell carcinoma with lymph metastases].Beijing da xue xue bao. Yi xue ban = Journal of Peking University. Health sciences · 2026
    Article
  8. Review
  9. Article
  10. Article
  11. Review
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Review
  19. Article
  20. Article

131 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

41 authors at 4 institutions in 1 country.

Steffen Durinck *Molecular Biology Department, Genentech, Inc., South San Francisco, California, USA.
Eric W Stawiski *Molecular Biology Department, Genentech, Inc., South San Francisco, California, USA.
Andrea Pavía-Jiménez *Kidney Cancer Program, University of Texas Southwestern Medical Center, Dallas, Texas, USA.
Zora Modrusan *Molecular Biology Department, Genentech, Inc., South San Francisco, California, USA.
Payal Kapur *Kidney Cancer Program, University of Texas Southwestern Medical Center, Dallas, Texas, USA.
Bijay S JaiswalMolecular Biology Department, Genentech, Inc., South San Francisco, California, USA.
Na ZhangMolecular Biology Department, Genentech, Inc., South San Francisco, California, USA.
Vanina Toffessi-TcheuyapKidney Cancer Program, University of Texas Southwestern Medical Center, Dallas, Texas, USA.
Thong T NguyenMolecular Biology Department, Genentech, Inc., South San Francisco, California, USA.
Kanika Bajaj PahujaMolecular Biology Department, Genentech, Inc., South San Francisco, California, USA.
Ying-Jiun ChenMolecular Biology Department, Genentech, Inc., South San Francisco, California, USA.
Sadia SaleemKidney Cancer Program, University of Texas Southwestern Medical Center, Dallas, Texas, USA.
Subhra ChaudhuriMolecular Biology Department, Genentech, Inc., South San Francisco, California, USA.
Sherry HeldensMolecular Biology Department, Genentech, Inc., South San Francisco, California, USA.
Marlena JacksonMolecular Biology Department, Genentech, Inc., South San Francisco, California, USA.
Samuel Peña-LlopisKidney Cancer Program, University of Texas Southwestern Medical Center, Dallas, Texas, USA.
Joseph GuilloryMolecular Biology Department, Genentech, Inc., South San Francisco, California, USA.
Karen ToyMolecular Biology Department, Genentech, Inc., South San Francisco, California, USA.
Connie HaMolecular Biology Department, Genentech, Inc., South San Francisco, California, USA.
Corissa J HarrisMolecular Biology Department, Genentech, Inc., South San Francisco, California, USA.
Eboni HollomanKidney Cancer Program, University of Texas Southwestern Medical Center, Dallas, Texas, USA.
Haley M HillKidney Cancer Program, University of Texas Southwestern Medical Center, Dallas, Texas, USA.
Jeremy StinsonMolecular Biology Department, Genentech, Inc., South San Francisco, California, USA.
Celina Sanchez RiversMolecular Biology Department, Genentech, Inc., South San Francisco, California, USA.
Vasantharajan JanakiramanMolecular Biology Department, Genentech, Inc., South San Francisco, California, USA.
Weiru WangStructural Biology Department, Genentech, Inc., South San Francisco, California, USA.
Lisa N KinchKidney Cancer Program, University of Texas Southwestern Medical Center, Dallas, Texas, USA.
Nick V GrishinKidney Cancer Program, University of Texas Southwestern Medical Center, Dallas, Texas, USA.
Peter M HavertyBioinformatics and Computational Biology Department, Genentech, Inc., South San Francisco, California, USA.
Bernard ChowMolecular Biology Department, Genentech, Inc., South San Francisco, California, USA.
Julian S GehringBioinformatics and Computational Biology Department, Genentech, Inc., South San Francisco, California, USA.
Jens ReederBioinformatics and Computational Biology Department, Genentech, Inc., South San Francisco, California, USA.
Gregoire PauBioinformatics and Computational Biology Department, Genentech, Inc., South San Francisco, California, USA.
Thomas D WuBioinformatics and Computational Biology Department, Genentech, Inc., South San Francisco, California, USA.
Vitaly MargulisKidney Cancer Program, University of Texas Southwestern Medical Center, Dallas, Texas, USA.
Yair LotanKidney Cancer Program, University of Texas Southwestern Medical Center, Dallas, Texas, USA.
Arthur SagalowskyKidney Cancer Program, University of Texas Southwestern Medical Center, Dallas, Texas, USA.
Ivan PedrosaKidney Cancer Program, University of Texas Southwestern Medical Center, Dallas, Texas, USA.
Frederic J de SauvageMolecular Oncology Department, Genentech, Inc., South San Francisco, California, USA.
James BrugarolasKidney Cancer Program, University of Texas Southwestern Medical Center, Dallas, Texas, USA.
Somasekar SeshagiriMolecular Biology Department, Genentech, Inc., South San Francisco, California, USA.
The University of Texas Southwestern Medical Center · USHoward Hughes Medical Institute · USMolecular Oncology (United States) · USSouthwestern Medical Center · US

Funding

UT Southwestern Medical Center Simmons Comprehensive Cancer CenterP30CA142543 · NCI · UT SOUTHWESTERN MEDICAL CENTER · PI Sandi Leigh Pruitt · 2010 to 2026
$53.7M
NON-INVASIVE PHYSIOLOGIC PREDICTORS OF AGGRESSIVENESS IN RENAL CELL CARCINOMAR01CA154475 · NCI · UT SOUTHWESTERN MEDICAL CENTER · PI PEDROSA, IVAN · 2011 to 2024
$4.3M
Evaluation of the BAP1 tumor suppressor gene in renal cell carcinomaR01CA175754 · NCI · UT SOUTHWESTERN MEDICAL CENTER · PI BRUGAROLAS, JAMES · 2014 to 2018
$1.6M
NCI NIH HHS 1R01CA175754NCI NIH HHS 5P30CA142543NCI NIH HHS 5R01CA154475-04NCI NIH HHS P30 CA142543NCI NIH HHS R01 CA154475NCI NIH HHS R01 CA175754
6 · The paper itself

Abstract

To further understand the molecular distinctions between kidney cancer subtypes, we analyzed exome, transcriptome and copy number alteration data from 167 primary human tumors that included renal oncocytomas and non-clear cell renal cell carcinomas (nccRCCs), consisting of papillary (pRCC), chromophobe (chRCC) and translocation (tRCC) subtypes. We identified ten significantly mutated genes in pRCC, including MET, NF2, SLC5A3, PNKD and CPQ. MET mutations occurred in 15% (10/65) of pRCC samples and included previously unreported recurrent activating mutations. In chRCC, we found TP53, PTEN, FAAH2, PDHB, PDXDC1 and ZNF765 to be significantly mutated. Gene expression analysis identified a five-gene set that enabled the molecular classification of chRCC, renal oncocytoma and pRCC. Using RNA sequencing, we identified previously unreported gene fusions, including ACTG1-MITF fusion. Ectopic expression of the ACTG1-MITF fusion led to cellular transformation and induced the expression of downstream target genes. Finally, we observed upregulation of the anti-apoptotic factor BIRC7 in MiTF-high RCC tumors, suggesting a potential therapeutic role for BIRC7 inhibitors.

Indexed as

Gene Expression ProfilingGene Expression Regulation, NeoplasticMutationAdenoma, OxyphilicAmino Acid SequenceBase SequenceBiomarkers, TumorCarcinoma, Renal CellDNA, NeoplasmGene DosageGenomic InstabilityHumansKidney NeoplasmsMolecular Sequence DataNeoplasm ProteinsOncogene Proteins, FusionACTG1-MITF fusion protein, humanBiomarkers, TumorDNA, NeoplasmMET protein, humanNeoplasm ProteinsOncogene Proteins, FusionProto-Oncogene Proteins c-met

Identifiers

PMID25401301
PMCPMC4489427
OpenAlexW2068059571

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.